Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in patients with leukaemic cutaneous T-cell lymphoma
YC Tsai, T Schlaepfer, D Ignatova… - British Journal of …, 2023 - academic.oup.com
Background Extracorporeal photopheresis (ECP) has emerged as a systemic first-line
immunomodulatory therapy in leukaemic cutaneous T-cell lymphoma (L-CTCL) and is now …
immunomodulatory therapy in leukaemic cutaneous T-cell lymphoma (L-CTCL) and is now …
[HTML][HTML] ECP versus ruxolitinib in steroid-refractory chronic GVHD–a retrospective study by the EBMT transplant complications working party
O Penack, C Peczynski, W Boreland… - Bone Marrow …, 2024 - nature.com
Ruxolitinib has become the new standard of care for steroid-refractory and steroid-
dependent chronic GVHD (SR-cGVHD). Our aim was to collect comparative data between …
dependent chronic GVHD (SR-cGVHD). Our aim was to collect comparative data between …
[HTML][HTML] ECP versus ruxolitinib in steroid-refractory acute GVHD–a retrospective study by the EBMT transplant complications working party
O Penack, C Peczynski, W Boreland… - Frontiers in …, 2023 - frontiersin.org
Introduction Extracorporal Photophoresis (ECP) is in clinical use for steroid-refractory and
steroid-dependent acute GVHD (SR-aGVHD). Based on recent Phase-III study results …
steroid-dependent acute GVHD (SR-aGVHD). Based on recent Phase-III study results …
[HTML][HTML] Treatment of graft versus host disease with photopheresis interferes in voriconazole therapeutic drug monitoring: A case study
A Sassone, J Testard, A Saulo, A Julia… - Practical Laboratory …, 2023 - Elsevier
Extracorporeal photopheresis is an established procedure for refractory graft-versus-host
disease, a major complication associated with notable morbidity and mortality in patients …
disease, a major complication associated with notable morbidity and mortality in patients …